In This Article
In April 2025, the FDA issued an alert about compounded topical finasteride products and adverse event reports. If you use or are considering topical finasteride, here's what you need to know — with the context that the headlines often leave out.
What the FDA Alert Says
The FDA flagged adverse event reports associated with compounded topical finasteride products, including sexual side effects similar to those seen with oral finasteride. The key word here is compounded — there is currently no FDA-approved topical finasteride product. All topical finasteride on the market is produced by compounding pharmacies, which means it hasn't undergone the same rigorous FDA review for safety, dosing consistency, and absorption rates.
Important Context
This alert is less alarming when you understand the landscape:
Compounded ≠ FDA-approved. Compounded topical finasteride varies significantly between pharmacies in concentration, formulation, and absorption. Without standardized manufacturing, side effect profiles are harder to predict. (This parallels the broader FDA enforcement trend around compounded medications.)
Side effect rates with topical are generally lower. Published research on topical finasteride typically reports sexual side effects in less than 2% of users, compared to 2–4% with oral finasteride. The topical route does result in lower systemic DHT reduction, which is likely why side effects tend to be milder — though it also means efficacy may be slightly lower for some patients.
The alert doesn't mean topical finasteride is dangerous. It means the FDA is highlighting that compounded products carry inherent uncertainty, and that patients and providers should be aware of the reported side effects. This is responsible communication, not a ban.
Topical vs. Oral Finasteride: What We Know
For a full comparison of finasteride (oral) vs. minoxidil and combination approaches, see our detailed comparison article. In summary:
Oral finasteride (1 mg): FDA-approved, extensively studied, well-characterized side effect profile. The gold standard systemic treatment. Side effects occur in 2–4% of users and are typically reversible.
Topical finasteride (compounded): Not FDA-approved. Lower systemic exposure (and likely lower side effect rates), but less standardized dosing. The FDA alert applies specifically to these products.
If you're using topical finasteride and experiencing side effects, talk to your provider. Options include switching to the FDA-approved oral version (where the dosing and side effects are well-characterized), adjusting the topical concentration, or exploring other treatments like minoxidil.
How to Get Safe Treatment
The safest path for hair loss treatment in 2026:
Use FDA-approved medications when possible. Oral finasteride (Propecia) and topical minoxidil (Rogaine) have decades of safety data.
If using compounded products, verify the pharmacy. State-licensed, with transparent ingredient sourcing and consistent formulations.
Work with a licensed provider. Telehealth platforms that prescribe hair loss medications can monitor your response and adjust treatment as needed — this ongoing relationship is valuable, especially when using medications with potential side effects.
The science of hair loss treatment is advancing rapidly — our article on the future of hair loss treatments covers what's in the pipeline for 2026 and beyond.
Compare telehealth providers that prescribe FDA-approved hair loss treatments — finasteride, minoxidil, and custom formulas.
Compare Hair Loss Providers →Bottom line: The FDA alert is a reminder to be thoughtful about compounded products — not a reason to panic. Safe, effective hair loss treatment is available through FDA-approved medications and reputable telehealth providers. If you're concerned, talk to your provider about your specific situation.